Virginia Commonwealth University

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Virginia Commonwealth University sits in the top decile of US sponsors by registered trial count (#63 of 15,742 sponsors by registered trial count).

558 total trials 77 currently recruiting 380 completed early-phase tilt top decile by trial count

Virginia Commonwealth University: 558 sponsored US clinical trials, 77 recruiting.

Virginia Commonwealth University sponsors 558 registered US clinical trials on ClinicalTrials.gov, 77 of them currently recruiting, and 380 completed. 35 of these trials are in Phase 3-4 (later-stage) and 145 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obesity, with 8 trials.

Top-decile sponsor footprint

Virginia Commonwealth University ranks in the top decile of sponsors by registered trial count (#63 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 45/100

380 of 462 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (82.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

558 total, page 8 of 12

COMPLETED

Hemosonics- VCU Cardiac Surgery Clinical Study

NCT02392247
TERMINATED Phase 3

Melatonin Supplementation for Cancer-related Fatigue in Patients Receiving Radiotherapy

NCT02332928
COMPLETED NA

Physical Activity as Self-Management Approach to Improve Health Outcomes in AML

NCT02584296
TERMINATED NA

Wellness Engagement Project, Petersburg

NCT02652845
COMPLETED Phase 1

Dimethyl Fumarate, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

NCT02337426
COMPLETED Phase 1

Neoadjuvant Chemotherapy Followed by Radiation Therapy and Gemcitabine/Sorafenib/Vorinostat in Pancreatic Cancer

NCT02349867
COMPLETED NA

Evaluation of a Family-based Pediatric Obesity Program: TEENS+

NCT02262013
COMPLETED Phase 1

Phase I Study of Neoadjuvant Radiotherapy With 5-Fluorouracil for Rectal Cancer

NCT02270606
COMPLETED Phase 2

Safety and Efficacy of IMM 124-E for Patients With Severe Alcoholic Hepatitis

NCT01968382
TERMINATED NA

CBT-I Intervention for Insomnia in Newly Diagnosed Cancer Patients

NCT02410564
COMPLETED NA

Acute Effects of High Intensity Interval Exercise on Executive Function

NCT02270528
COMPLETED NA

Rapidly Absorbing Polyglactin 910 Versus Poliglecaprone 25 for Laceration Repair

NCT03184077
COMPLETED Phase 2

Interleukin-1 Blockade in HF With Preserved EF

NCT02173548
TERMINATED Phase 4

Study of Using Long Acting Antihistamine to Treat Opioid Induced Itching

NCT01825655
COMPLETED Phase 2

Interleukin-1 (IL-1) Blockade in Acute Myocardial Infarction (VCU-ART3)

NCT01950299
COMPLETED Phase 1

5HT2CR Balance in Brain Connectivity in Cocaine Dependence

NCT03921151
COMPLETED

Autonomic Dysfunction in Non-Alcoholic Fatty Liver Disease

NCT02132780
COMPLETED

HBV-HIV Coinfection Research Network

NCT01924455
COMPLETED Phase 2

Vitamin C Infusion for Treatment in Sepsis Induced Acute Lung Injury

NCT02106975
COMPLETED NA

Initial Efficacy Study of Supporting Play, Exploration, & Early Development Intervention

NCT02153736
TERMINATED NA

Efficacy of a Patient Education Video

NCT02114827
COMPLETED

CT Imaging Evaluation of Humerus Fractures

NCT02170545
COMPLETED Phase 2

Interleukin-1 Blockade in Recently Decompensated Heart Failure

NCT01936909
COMPLETED

Implantable Cardioverter Defibrillator (ICD) Function During Ventricular Assist Device (VAD) Implantation

NCT01576562
COMPLETED Phase 2

Striatal Effective Connectivity to Predict Treatment Response in Cocaine Misuse

NCT02080819
COMPLETED Phase 2

Interleukin (IL)-1 Blockade in Acute Heart Failure (Anakinra ADHF)

NCT01936844
COMPLETED NA

Stress Management for Cancer Survivors

NCT01888523
COMPLETED Phase 2

The Role of N-acetyl-l-cysteine (NAC) as an Adjuvant to Opioid Treatment in Patients With Chronic Neuropathic Pain

NCT01840345
TERMINATED NA

Communication Training in Promoting Employment Retention Among Cancer Patients

NCT02895490
COMPLETED Phase 1

Alpha-1 Anti-Trypsin (AAT) Treatment in Acute Myocardial Infarction

NCT01936896
COMPLETED

Intestinal Ischemia as a Stimulus for Systemic Inflammatory Response After Cardiac Arrest

NCT01944605
COMPLETED NA

Efficacy of an Organizational Skills Intervention for Middle School Students With ADHD

NCT02150668
TERMINATED NA

Developing an Online Clinical Trial Specific Question Prompt List

NCT02030379
COMPLETED NA

Communicating About Choices in Transplantation

NCT01853007
COMPLETED NA

CT in Diagnosing Patients With Lung Cancer

NCT01888510
COMPLETED NA

Pilot Study of Laparoscopic Gastric Plication in Adolescents With Severe Obesity

NCT01980758
COMPLETED NA

Increasing Communication About Live Donor Kidney Transplant

NCT01855438
TERMINATED

Insulin Resistance Before and During Pregnancy in Women With Polycystic Ovary Syndrome

NCT01475565
COMPLETED Phase 2

Sorafenib, Valproic Acid, and Sildenafil in Treating Patients With Recurrent High-Grade Glioma

NCT01817751
COMPLETED NA

Interleukin-1 Blockade With Canakinumab to Improve Exercise Capacity in Patients With Chronic Systolic Heart Failure and Elevated High Sensitivity C-reactive Protein (Hs-CRP)

NCT01900600
COMPLETED

Point of Care (POC) Biomarkers of Ischemia

NCT02039882
COMPLETED NA

Erythromycin in Parkinson's Disease

NCT02005029
TERMINATED Phase 4

Nesiritide and Renal Function After the Total Artificial Heart

NCT01836809
TERMINATED NA

Stereotactic Body Radiation Therapy in Treating Patients With Low- and Intermediate-Risk Prostate Cancer

NCT01737151
COMPLETED NA

Trial of Scrambler Therapy or Sham Treatment for Low Back Pain

NCT01896687
COMPLETED NA

Goal Setting for Health Behavior and Psychosocial Issues in Primary Care

NCT01825746
COMPLETED NA

Evaluation of a Skill-Building, Supportive, and Educational Intervention for Couples

NCT01935609
TERMINATED NA

Compassionate Same-Day Evaluation & Delivery of XRT for Bony Metastasis in Hospice Patients

NCT01760941
COMPLETED Phase 1

Safety Study of Octreotide Injection to Prevent GI Bleeding in Patients With Left Ventricular Assist Device (LVAD)

NCT01707225
COMPLETED NA

Intervention to Promote Survivor Resilience and Adjustment: Efficacy Evaluation

NCT01935583
← Previous Page 8 of 12 Next →

Phase Distribution

PhaseTrial count
Phase 1 80
Phase 2 65
Phase 3 13
Phase 4 22

Therapeutic Areas

Obesity 8
Stress 5
Breast Cancer 5
Heart Failure 5
Peripheral Vascular Diseases 3
Violence 3
Pediatric Obesity 3
Traumatic Brain Injury 3
Cirrhosis 3
Kidney Transplant; Complications 3

What is open in the Virginia Commonwealth University pipeline

77 recruiting of 558 indexed (14% open); 380 completed (68%).

Phase mix: 35 late (III/IV) vs 145 early (I/II) (early-phase heavy).

Top condition: Obesity (8 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Virginia Commonwealth University: open-pipeline peers nationwide

Peers matched on 558 registered trials and 14% open enrollment, not the therapeutic-area sidebar.

Virginia Commonwealth University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0200400600 5%10%15%20%25% Total trials Recruiting share Virginia Commonwealth UniversityAmgenMerck Sharp & DohmeUniversity of Maryland, BaltimoreOhio State UniversityLindenwood UniversityBeiGeneReproductive Medicine Associates of New JerseyUniversity of Cincinnati
Virginia Commonwealth University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Virginia Commonwealth University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 558 trials (± recruiting share)

Sponsors near 14% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Virginia Commonwealth University page

558 registered trials is a research-attention snapshot, not an endorsement of Virginia Commonwealth University or any single study.

  • 77 of Virginia Commonwealth University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Obesity is the condition Virginia Commonwealth University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Obesity trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Virginia Commonwealth University pipeline card: 558 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.